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472Objective: The incidence of hospital-acquired Clostridium difficile infection (CDI) has increased rapidly over
the past decade; patients undergoing major surgery, including coronary artery bypass grafting (CABG), are at
particular risk. Intravenous vancomycin exposure has been identified as an independent risk factor for CDI,
but this is controversial. It is not known whether vancomycin administered for surgical site infection prophylaxis
increases the risk of CDI.
Methods: Using data from the Premier Perspective Comparative Database, we assembled a cohort of 69,807
patients undergoing CABG surgery between 2004 and 2010 who received either a cephalosporin alone
(65.1%) or a cephalosporin plus vancomycin (34.9%) on the day of surgery. Patients were observed for CDI
until discharge from the index hospitalization. In these groups, we evaluated the comparative rate of postoper-
ative CDI with Cox models; confounding was addressed using propensity scores.
Results: In all, 77 (0.32%) of the 24,393 patients receiving a cephalosporin plus vancomycin and 179 (0.39%)
of the 45,414 patients receiving a cephalosporin alone had postoperative CDI (unadjusted hazard ratio [HR],
0.73; 95% confidence interval [CI], 0.56-0.95). After adjusting for confounding variables with either propensity
score matching or stratification, there was no meaningful association between adjuvant vancomycin exposure
and postoperative CDI (HR, 0.85; 95% CI, 0.61-1.19; and HR, 0.85; 95% CI, 0.63-1.15, respectively). Results
of multiple sensitivity analyses were similar to the main findings.
Conclusions: After adjustment for patient and surgical characteristics, a short course of prophylactic vancomy-
cin was not associated with an increased risk of CDI among patients undergoing CABG surgery. (J Thorac
Cardiovasc Surg 2013;146:472-8)Clostridium difficile infection (CDI) occurs commonly
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The Journal of Thoracic and Cardiovascular Surgfrequency during the past decade.1 Patients undergoing ma-
jor surgery, including cardiac surgery, are at particular
risk.2,3 For these patients, CDI lengthens hospitalization,2
increases the amount of time patients spend in the intensive
care unit,2 prolongs mechanical ventilation,2 can cause the
need for readmission,4 and increases mortality.3 Therefore,
identifying risk factors for the development of CDI and de-
veloping strategies to decrease its occurrence in the postop-
erative period are urgently needed.
Antibiotic exposure is the single most important risk
factor for the development of CDI.5,6 Antibiotics alter the
native colonic flora, which allows C difficile to
proliferate.7 Studies have demonstrated an association be-
tween short courses of perioperative antibiotic use and the
risk of CDI.8 Indeed, C difficile can proliferate after just
a single dose of antibiotics for prophylaxis in surgery.9 In
contrast, the prophylactic administration of antibiotics has
demonstrated benefit in the prevention of surgical site infec-
tion (SSI) after cardiac and other surgical procedures. On
the basis of evidence from randomized controlled clinical
trials, The Society of Thoracic Surgeons guidelines recom-
mend prophylaxis with a beta-lactam antibiotic for thisery c August 2013
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CDI ¼ Clostridium difficile infection
CI ¼ confidence interval
HR ¼ hazard ratio
SSI ¼ surgical site infection
Bateman et al Perioperative Managementpurpose, including a cephalosporin among nonallergic pa-
tients, with the addition of vancomycin among those with
known or presumed staphylococcal colonization, those
from institutions with a high incidence of methicillin-
resistant staphylococcal infections, those ‘‘susceptible’’ to
colonization, or those receiving a prosthetic valve.10
There is concern that excessive use of vancomycin for
SSI may lead to an increase in antibiotic resistance in Staph-
ylococcus and Enterococcus organisms,11,12 which has led
to calls to curb its routine use for prophylaxis.13 An addition
potential concern is that vancomycin exposuremay increase
the risk for CDI. Exposure to intravenous vancomycin has
recently been identified as an independent risk factor for
the development of CDI in several studies of hospitalized
patients,14-16 but this remains controversial. Currently,
there are limited data on whether adjuvant vancomycin
used for SSI prophylaxis increases risk for CDI. We
therefore sought to define the comparative risk of CDI
associated with the adjunctive use of vancomycin as
a prophylactic antibiotic versus use of a cephalosporin
alone among patients undergoing coronary artery bypass
grafting (CABG).P
MMETHODS
Data Source
The study cohort was derived from the Premier Perspective Compara-
tive Database. The database includes approximately one sixth of all hospi-
talizations in the United States. The database contains information about
daily charges for all medications, procedures, and diagnostic tests conduct-
ed during each hospitalization, as well as patient demographic and hospital
characteristics, discharge diagnoses, and discharge status (including
death). Data are routinely audited, verified, and validated. Premier data
have been extensively used to study medication use and health outcomes
in the perioperative period.17-19 The use of this data set for research was
approved by the Institutional Review Board of the Brigham and
Women’s Hospital, Boston, Mass, and a Data Use Agreement was in place.
Cohort
We considered all patients who, during the course of a hospital stay, un-
derwent a CABG (identified by procedure code 36.1, or any subcode
thereof, from the International Classification of Diseases, ninth revision)
between January 1, 2004, and December 31, 2010. Because the database
does not record comorbidities or other information about patients at the
time of their admission, we excluded patients who underwent CABG on
the day of hospital admission, to allow time for accrual of information about
patients’ preoperative health status that might affect the choice of prophy-
lactic antibiotic. We also excluded patients who were exposed to any sys-
temic antibiotic from day 1 to the day before CABG to isolate the effectThe Journal of Thoracic and Caof the prophylactic antibiotics administered on the day of surgery. We fur-
ther limited our analysis to those patients that received either a cephalospo-
rin alone or a cephalosporin plus vancomycin, inasmuch as these are the
most common prophylactic antibiotic regimens administered on the day
of surgery in the United States and the ones that are in keeping with current
guidelines for patients without a beta-lactam allergy.10 Finally, we excluded
those patients who died, were discharged, or had CDI develop in the first 2
postoperative days, inasmuch as 2 days is the minimum plausible induction
time for CDI related to antibiotic exposure on the day of surgery.14
Classification of Drug Exposure and Study Outcome
Cephalosporin exposure was defined as charges on the day of surgery
for 1 of the following intravenous medications: cefazolin, ceftriaxone,
cefuroxime, cefadroxil, cefamandole, cefepime, cefonicid, cefoperazone,
cefotaxime, cefotetan, ceftazidime, ceftizoxime, cephalothin, cephapirin,
or cephradine. Vancomycin exposure was defined on the basis of charges
on the day of surgery for intravenous vancomycin.
The main study outcome was CDI 48 hours or more postoperatively.14
Our outcome was defined by the presence of all 3 of the following criteria:
(1) a discharge diagnosis code of CDI (ICD 9 CM 008.45), (2) a charge
code indicating that a stool study for C difficile toxin has been performed,
and (3) a charge code indicating that appropriate CDI therapy (oral or in-
travenous metronidazole or oral vancomycin) had been initiated at least
2 hospital days after surgery. The time of the outcome event was defined
by the third criterion, the date therapy was initiated.
Patient and Hospital-Level Covariates
We identified 5 groups of potential confounders: patient demographics,
chronic comorbid conditions, markers of coexisting disease/disease sever-
ity, characteristics of the surgical procedure, and hospital characteristics.
Demographics included age on admission, gender, marital status (classified
as married, single, or other), race (classified as white, black, or other), and
season and year of admission. The presence of chronic comorbid condi-
tions was identified by discharge diagnoses including liver disease, malig-
nancy, prior endocarditis, peripheral vascular disease, hemostatic disorder,
carotid artery stenosis, prior stroke, and prior myocardial infarction.20 The
Romano modification21 of the Charlson comorbidity index, a score indicat-
ing patients’ severity of comorbid conditions, was also calculated for each
patient.
Coexisting conditions and/or markers of disease severity were evaluated
with drug use and procedures before the day of surgery and included dia-
betes mellitus, chronic obstructive pulmonary disease, end-stage renal dis-
ease, angiotensin-converting enzyme inhibitors, angiotensin II receptor
blockers, aldosterone agonists, beta-blockers, calcium channel blockers,
loop diuretics, thiazide diuretics, aspirin, clopidogrel, dipyridamole, sta-
tins, fibrates, digoxin, antiarrhythmic medications (amiodarone, dronedar-
one, sotatol, procainamide, propafenone), proton pump inhibitor, H2
blocker, or sucralfate. We also assessed for preoperative charges for telem-
etry, echocardiogram, oxygen use, and intensive care use.
Surgical characteristics included type of admission (urgent/emergency
vs elective), number of grafts, whether the patient received a thoracic artery
graft, and whether the patient received an aortic, mitral, or tricuspid valve
repair or replacement concurrently with their CABG.
Hospital characteristics were also assessed. Hospitals affiliated with
medical schools accredited by the Association of American Medical Col-
leges Liaison Committee on Medical Education were classified as teaching
hospitals and nonteaching hospitals otherwise. Geographic region of the
hospital was classified as Midwest, Northeast, South, or West. Location
was defined as urban or rural. The annualized volume of CABG patients
treated by each hospital was estimated by dividing the total number of
CABG patients for each hospital during the study time period by the num-
ber of years that each hospital performed 1 or more CABG operations. Hos-
pitals were ranked in order of annualized volume andwere then categorized
into high-, medium- and low-volume hospital tertiles.22rdiovascular Surgery c Volume 146, Number 2 473
FIGURE 1. Patient flow chart. CABG, Coronary artery bypass graft; CDI,
Clostridium difficile infection.
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MStatistical Analysis
In all analyses, follow-up began 2 hospital days after the CABG proce-
dure. Patients were censored at the first of the outcome of interest, the time
of death, or the time of hospital discharge. To adjust for potentially impor-
tant baseline differences in those patients who received adjuvant vancomy-
cin and those who did not, we conducted 2 separate analyses using
propensity scores. For both analyses, a propensity score was estimated
using a logistic regression model in which use of vancomycin as an adju-
vant was the dependent variable and predicted based on all the covariates
noted above without further selection.
For the first analysis, patients exposed to cephalosporin plus vancomy-
cin were matched on propensity score to those exposed to cephalosporins
alone in a fixed 1:1 ratio using a nearest neighbor algorithm with a caliper
of .05 difference in propensity score.23 This resulted in a matched cohort of
40,152 patients. Cox regression modeling was then performed in the
matched cohort to calculate hazard ratio (HR) and 95% confidence interval
(CI) for postoperative CDI associated with vancomycin exposure. In the
second score analysis, all subjects with a propensity score value that corre-
sponded to the 2.5 percentile or lower of propensity score distribution in the
cephalosporin plus vancomycin group and the 97.5 percentile or higher of
the propensity score distribution in the cephalosporin only group were
identified and excluded from further analysis. This approach of trimming
patients from the tails of the propensity score has been shown to further de-
crease residual confounding.24 Propensity score deciles were then created
in the remaining cohort (n¼ 62,221). A multivariable Cox model was then
fit including deciles of propensity score as covariates, and HR and 95% CI
for CDI associated with vancomycin exposure were determined.
Sensitivity Analyses
We repeated our analysis in the subgroup of patients (n ¼ 58,320) ex-
posed to the most commonly used cephalosporin, cefazolin (ie, cefazolin
plus vancomycin vs cefazolin alone). We also repeated our analyses defin-
ing the onset of CDI based on time that the stool study was performed (as
opposed to the time that appropriate antibiotics were initiated). Finally, we
repeated our analyses defining CDI based on the presence of a diagnosis
code for CDI and initiation of appropriate therapy (without the requirement
for a charge code for a stool study). All analyses were performed using SAS
version 9.2 (SAS Institute, Inc, Cary, NC).RESULTS
Cohort Characteristics
Our cohort consisted of 69,807 patients who underwent
CABG between 2004 and 2010, of whom 24,393 (34.9%) re-
ceived adjuvant vancomycin and the remainder received
a cephalosporin alone (Figure 1). CDI developed in 256 pa-
tients overall. Postoperative CDI was associated with
increased risk of adverse outcome; 9.9% of patientswith post-
operative CDI died versus 1.7% of those that did not have
CDI. Length of stay was also substantially longer in those
whohadCDIcomparedwith thosewhodid not (median length
of stay [interquartile range] 22 days [range, 14-35 days] vs 9
[range, 8-13 days]). The proportion of patients who received
adjuvant vancomycin increased substantially during the study
period from 30.4% in 2004 to 42.7% in 2010 (Figure 2).FIGURE 2. Proportion of cephalosporin-exposed patients undergoing
coronary artery bypass grafting who received adjuvant vancomycin, by
year.Baseline Characteristics
There were notable differences in the baseline character-
istics of the 2 exposure groups (Table 1). Significant re-
gional differences in the use of vancomycin existed, with474 The Journal of Thoracic and Cardiovascular Surghigher incidence of use in the South and lower incidence
in the Northeast. Teaching and urban hospitals also used
vancomycin more commonly than did nonteaching and
rural hospitals. A larger fraction of patients exposed to van-
comycin were female and African American. Vancomycin-
exposed patients had a higher rate of preoperative intensive
care unit admission and were more often administered sup-
plemental oxygen, beta-blockers, antiarrhythmics, and
acid-suppression therapy. They also had slightly higher
rates of comorbidity including chronic obstructive pulmo-
nary disease, diabetes, prior myocardial infarction andery c August 2013
TABLE 1. Baseline characteristics of study population before and after PS matching
Characteristics
Before PS matching After PS matching
Cephalosporins
(N ¼ 45,414)
Cephalosporins þ
vancomycin
(N ¼ 24,393)
Difference between
cephalosporin and
cephalosporins þ
vancomycin
Cephalosporin
(N ¼ 20,076)
Cephalosporin þ
vancomycin
(N ¼ 20,076)
Difference between
cephalosporin and
cephalosporins þ
vancomycin
Age (y, mean  SD) 65.75 (11.07) 64.92 (11.12) 0.05 65.24 (11.07) 65.13 (11.08) 0.01
Male sex 33,858 (74.6%) 17,615 (72.2%) 2.4% 14,699 (73.2%) 14,673 (73.1%) 0.1%
Marital status
Married 27,388 (60.3%) 15,179 (62.2%) 1.9% 12,325 (61.4%) 12,476 (62.1%) 0.7%
Single 13,844 (30.5%) 7756 (31.8%) 1.3% 6137 (30.6%) 6225 (31.0%) 0.4%
Other 4182 (9.2%) 1458 (6.0%) 3.2% 1614 (8.0%) 1375 (6.8%) 1.2%
Race/ethnicity
White 32,777 (72.2%) 17,902 (73.4%) 1.2% 14,482 (72.1%) 14,665 (73.0%) 0.9%
African American 2642 (5.8%) 2253 (9.2%) 3.4% 1506 (7.5%) 1501 (7.5%) 0%
Other 9995 (22.0%) 4238 (17.4%) 4.6% 4088 (20.4%) 3910 (19.5%) 0.9%
Index CABG
Emergency admission 31,141 (68.6%) 16,069 (65.9%) 2.7% 13,351 (66.5%) 13,244 (66.0%) 0.5%
Thoracic graft 39,702 (87.4%) 20,856 (85.5%) 1.9% 17,387 (86.6%) 17,381 (86.6%) 0%
No. of grafts (mean  SD) 3.22 (1.09) 3.28 (1.08) 0.01 3.25 (1.08) 3.26 (1.09) 0.01
Repair/replacement of a valve
Mitral valve 1426 (3.1%) 831 (3.4%) 0.3% 661 (3.3%) 655 (3.3%) 0%
Aortic valve 3210 (7.1%) 1619 (6.6%) 0.5% 1328 (6.6%) 1311 (6.5%) 0.1%
Tricuspid valve 66 (0.1%) 60 (0.2%) 0.1% 38 (0.2%) 36 (0.2%) 0%
Percutaneous coronary
intervention
1809 (4.0%) 1131 (4.6%) 0.6% 917 (4.6%) 881 (4.4%) 0.2%
Previous CABG surgery 810 (1.8%) 502 (2.1%) 0.3% 389 (1.9%) 384 (1.9%) 0%
Preoperative LOS
(d, mean  SD)
2.79 (2.17) 3.04 (2.25) 0.08 2.91 (2.20) 2.88 (2.16) 0.04
Comorbidities
COPD/asthma* 4611 (10.2%) 2787 (11.4%) 1.2% 2189 (10.9%) 2098 (10.5%) 0.4%
Diabetes mellitusy 13,042 (28.7%) 7318 (30.0%) 1.3% 5846 (29.1%) 5790 (28.8%) 0.3%
End-stage renal diseasez 1045 (2.3%) 624 (2.6%) 0.3% 483 (2.4%) 469 (2.3%) 0.1%
Chronic liver disease 602 (1.3%) 367 (1.5%) 0.2% 302 (1.5%) 296 (1.5%) 0%
Cancer 4146 (9.1%) 2258 (9.3%) 0.2% 1837 (9.2%) 1824 (9.1%) 0.1%
Endocarditis 33 (0.1%) 29 (0.1%) 0% 19 (0.1%) 17 (0.1%) 0%
PVD 4006 (8.8%) 2482 (10.2%) 1.4% 1920 (9.6%) 1910 (9.5%) 0.1%
Hemostatic disorder 197 (0.4%) 139 (0.6%) 0.2% 110 (0.5%) 100 (0.5%) 0%
Prior MI 6390 (14.1%) 3701 (15.2%) 1.1% 2945 (14.7%) 2972 (14.8%) 0.1%
Prior stroke 1769 (3.9%) 1181 (4.8%) 0.9% 846 (4.2%) 875 (4.4%) 0.2%
Carotid artery stenosis 2158 (4.8%) 1697 (7.0%) 2.2% 1182 (5.9%) 1154 (5.7%) 0.2%
Charlson score 1.72 (1.49) 1.88 (1.55) 0.06 1.82 (1.54) 1.80 (1.52) 0.02
Inpatient use of drugs
or services before CABG
Telemetry 15,192 (33.5%) 8349 (34.2%) 0.7% 6658 (33.2%) 6818 (34.0%) 0.8%
Echocardiogram 13,731 (30.2%) 8781 (36.0%) 5.8% 6770 (33.7%) 6568 (32.7%) 1%
Oxygen use 14,337 (31.6%) 9429 (38.7%) 7.1% 7360 (36.7%) 7444 (37.1%) 0.4%
ICU 22,075 (48.6%) 12,985 (53.2%) 4.6% 10,797 (53.8%) 10,527 (52.4%) 1.4%
ACE inhibitor 16,775 (36.9%) 9437 (38.7%) 1.8% 7520 (37.5%) 7596 (37.8%) 0.3%
Angiotensin receptor blocker 4408 (9.7%) 2488 (10.2%) 0.5% 2006 (10.0%) 1989 (9.9%) 0.1%
Dipyridamole 690 (1.5%) 186 (0.8%) 0.7% 179 (0.9%) 181 (0.9%) 0%
Aldosterone agonist 983 (2.2%) 602 (2.5%) 0.3% 448 (2.2%) 460 (2.3%) 0.1%
Aspirin 27,024 (59.5%) 13,976 (57.3%) 2.2% 11,757 (58.6%) 11,851 (59.0%) 0.4%
Beta-blocker 33,325 (73.4%) 18,605 (76.3%) 2.9% 15,012 (74.8%) 15,030 (74.9%) 0.1%
Calcium channel blocker 8562 (18.9%) 4959 (20.3%) 1.4% 3941 (19.6%) 3909 (19.5%) 0.1%
Clopidogrel 6568 (14.5%) 3266 (13.4%) 1.1% 2756 (13.7%) 2756 (13.7%) 0%
Digoxin 1823 (4.0%) 903 (3.7%) 0.3% 766 (3.8%) 734 (3.7%) 0.1%
(Continued)
Bateman et al Perioperative Management
The Journal of Thoracic and Cardiovascular Surgery c Volume 146, Number 2 475
P
M
TABLE 1. Continued
Characteristics
Before PS matching After PS matching
Cephalosporins
(N ¼ 45,414)
Cephalosporins þ
vancomycin
(N ¼ 24,393)
Difference between
cephalosporin and
cephalosporins þ
vancomycin
Cephalosporin
(N ¼ 20,076)
Cephalosporin þ
vancomycin
(N ¼ 20,076)
Difference between
cephalosporin and
cephalosporins þ
vancomycin
Fibrate 1643 (3.6%) 983 (4.0%) 0.4% 789 (3.9%) 800 (4.0%) 0.1%
Loop diuretic 7281 (16.0%) 4235 (17.4%) 1.4% 3310 (16.5%) 3324 (16.6%) 0.1%
Thiazide diuretic 4218 (9.3%) 2537 (10.4%) 1.1% 1981 (9.9%) 1998 (10.0%) 0.1%
Statin 29,716 (65.4%) 15,836 (64.9%) 0.5% 12,883 (64.2%) 12,959 (64.5%) 0.3%
Antiarrhythmic medication 3759 (8.3%) 3558 (14.6%) 6.3% 2397 (11.9%) 2260 (11.3%) 0.6%
Proton-pump inhibitor 14,438 (31.8%) 8840 (36.2%) 4.4% 6749 (33.6%) 6638 (33.1%) 0.5%
H2 blocker 6402 (14.1%) 4693 (19.2%) 5.1% 3451 (17.2%) 3511 (17.5%) 0.3%
Sucralfate 220 (0.5%) 100 (0.4%) 0.1% 86 (0.4%) 85 (0.4%) 0%
Hospital characteristics
Teaching hospital 25,551 (56.3%) 14,907 (61.1%) 4.8% 11,429 (56.9%) 11,353 (56.6%) 0.3%
Urban hospital 41,072 (90.4%) 23,076 (94.6%) 4.2% 18,787 (93.6%) 18,759 (93.4%) 0.2%
High volume center 33,239 (73.2%) 17,099 (70.1%) 3.1% 13,721 (68.3%) 13,851 (69.0%) 0.7%
Region
Midwest 7221 (15.9%) 3756 (15.4%) 0.5% 3457 (17.2%) 3661 (18.2%) 1%
Northeast 12,152 (26.8%) 1726 (7.1%) 19.7% 2000 (10.0%) 1726 (8.6%) 1.4%
South 16,459 (36.2%) 15,132 (62.0%) 25.8% 11,127 (55.4%) 10,944 (54.5%) 0.9%
West 9582 (21.1%) 3779 (15.5%) 5.6% 3492 (17.4%) 3745 (18.7%) 1.3%
PS, Propensity score; SD, standard deviation; CABG, coronary artery bypass graft; LOS, length of stay; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular
disease;MI,myocardial infarction; ICU, intensive care unit; ACE, angiotensin-converting enzyme. *Based on preoperative beta-agonist, inhaled steroids, leukotriene inhibitors,
ipratropium, or theophylline exposure. yBased on preoperative insulin or oral hypoglycemic exposure. zBased on preoperative dialysis, erythropoietin, or darbepoetin.
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Mstroke, peripheral vascular disease, and carotid artery steno-
sis. They were, however, on average slightly younger than
those exposed to cephalosporins alone. These imbalances
were no longer present in the propensity score–matched co-
hort with a difference in proportions between the exposure
groups of less than 2% for all covariates (Table 1). Duration
of perioperative administration was similar between the 2
groups, suggesting that this is not an important confounder
in our analysis; antibiotics were continued for 3 or more
days in 18.5% of the cephalosporin-only group and
16.3% of the cephalosporin with vancomycin group.Association of Vancomycin Exposure With C difficile
Infection
Overall, 179 (0.39%) patients in the cephalosporin group
and 77 (0.32%) patients in the cephalosporin plus vancomy-
cin group had CDI. Vancomycin-treated patients had an un-
adjusted HR for CDI of 0.73 (95% CI, 0.56-0.95) (Table 2).
After adjustment with propensity score matching or stratifi-
cation, there was no meaningful association between adju-
vant vancomycin exposure and CDI (HR, 0.85; 95% CI,
0.61-1.19; and HR, 0.85; 95% CI, 0.63-1.15, respectively).Sensitivity Analyses
When we restricted our analyses to the patients exposed
to cefazolin, the most commonly used cephalosporin in our
cohort, the results were similar to those in the full cohort
(Table 3).476 The Journal of Thoracic and Cardiovascular SurgLikewise, results were very similar when we defined on-
set of CDI based on the time that the stool study was per-
formed (in propensity-matched analysis, HR, 0.88; 95%
CI, 0.63-1.23) and when we defined CDI based on the pres-
ence of a diagnosis code for CDI and charge codes for ap-
propriate antibiotic therapy, without the requirement for
a charge code for a stool study (in propensity-matched anal-
ysis, HR, 0.86; 95% CI, 0.61-1.20).DISCUSSION
In this large, nationally representative, hospital-based co-
hort study of 69,807 patients who underwent CABG be-
tween 2004 and 2010, we did not observe an increase in
risk for CDI from the adjuvant use of vancomycin for SSI
prophylaxis compared with cephalosporin use alone. These
data suggest that concern about increased risk of CDI
should not factor into clinicians’ decision making regarding
whether to administer vancomycin as an adjuvant to cepha-
losporins in this setting, especially given vancomycin’s po-
tential benefits for appropriately selected patients.
The lack of association between vancomycin exposure
and CDI in our study contrasts with the findings of other
studies identifying vancomycin exposure as an independent
risk factor for CDI.14-16,25 These studies evaluated patients
hospitalized for a broad range of indications where
vancomycin was likely used for therapeutic indications14-16
and where vancomycin may have actually reflected
illness severity, which itself is a risk factor for theery c August 2013
TABLE 2. Hazard ratios of developing C difficile in patients treated with cephalosporin þ vancomycin as compared with patients treated with
cephalosporins only
No. of patients
No. of events
HR (95% CI)Cephalosporin Cephalosporin þ vancomycin
Unadjusted 69,807 179 77 0.73 (0.56-0.95)
Adjusted
Age, sex, race, and calendar year 69,807 179 77 0.75 (0.57-0.98)
PS matching 40,152 73 64 0.85 (0.61-1.19)
PS stratification* 62,221 164 66 0.85 (0.63-1.15)
HR, Hazard ratio; CI, confidence interval; PS, propensity score. *All patients with a PS  the value that corresponds to 2.5 percentile of the PS distribution in the cephalosporin
plus vancomycin group and the PS value that corresponds to 97.5 percentile of the PS distribution in the cephalosporin group were excluded from this analysis (see text for more
details).
Bateman et al Perioperative Managementdevelopment of CDI. In contrast, we evaluated the use of
vancomycin as a prophylactic regimen in a cohort in
which more than 80% of patients treated received this
therapy for 2 days or less. Because duration of antibiotic
exposure is strongly correlated with the risk of CDI,16 it
may be that the short course of exposure to vancomycin ac-
counts for the lack of increased risk observed in our study.
Nevertheless, given the sheer prevalence of vancomycin use
(45% of patients at the end of the study cohort), it is reas-
suring that this treatment strategy does not appear to expose
patients to excess risk.
During the study period from 2004 to 2010, we docu-
mented a nearly 50% increase in the administration of
adjuvant vancomycin. Although our study did not document
increased risk for CDI associated with its use, other con-
cerns about the widespread use of vancomycin including
selection of vancomycin-resistant Enterococcus and Staph-
ylococcus, outcomes that we were unable to assess with our
data, persist.11,12 Our analysis does indicate highly
heterogeneous use among regions and hospital types,
suggesting the need for better definition of the patient
groups most likely to benefit from the adjuvant use of this
therapy in preventing endocarditis and deep mediastinal
wound infections.26,27
Our study should be interpreted in the context of the lim-
itations inherent in its design. Although the Premier Data-
base contains highly granular data on the use of
medications, laboratory test, and procedures, the informa-
tion is collected for billing purposes and lacks certainTABLE 3. Hazard ratios of developing C difficile in patients treated with ce
only
No. of patients
Unadjusted 58,320
Adjusted
Age, sex, race, and calendar year 58,320
PS matching 32,278
PS stratification* 50,442
HR, Hazard ratio; CI, confidence interval; PS, propensity score. *All patients with a PS  t
vancomycin group and the PS value that corresponds to 97.5 percentile of the PS distribut
The Journal of Thoracic and Caclinical information such as the indication for the adminis-
tration of adjuvant vancomycin. While we used rigorous
statistical methodology, in the form of propensity scores,
to adjust for baseline differences between those who did
and did not receive adjuvant vancomycin, there may be un-
measured or unknown confounders that biased our results.
We also did not have direct microbiologic data to confirm
the diagnosis of CDI; previous data suggest a high sensitiv-
ity and specificity for diagnosis codes indicating CDI.28-30
However, to increase the positive predictive value of our
outcome definition, we required a charge code indicating
stool study for C difficile toxin and a charge code
indicating appropriate CDI therapy.29,30 We only capture
cases of CDI that occur during the index hospitalization.
Although elevation in CDI risk persists for approximately
3 months after antibiotic exposure, the greatest risk is in
the weeks immediately after antibiotic exposure.31 Because
of the extended postoperative hospital stay after CABG, we
likely capture a large fraction of postoperative CDI cases.
While, after accounting for relevant confounders, our study
cannot preclude as much as a 19% increase in the risk of
CDI associated with adjuvant vancomycin, it is unlikely
that a better powered study could be performed with avail-
able data sources. The Premier Database is the largest of its
kind, capturing detailed information on approximately one
sixth of all hospitalizations in the United States. Thus, while
the present study cannot definitely rule out a small increase
in risk of CDI associated with adjuvant vancomycin, it pro-
vides high-quality evidence to guide clinicians with respectfazolinþ vancomycin as compared with patients treated with cefazolin
No. of events
HR (95% CI)Cefazolin Cefazolin þ vancomycin
162 59 0.74 (0.55-1.00)
162 59 0.75 (0.56-1.01)
65 55 0.83 (0.58-1.18)
142 52 0.80 (0.57-1.10)
he value that corresponds to 2.5 percentile of the PS distribution in the cefazolin plus
ion in the cefazolin group were excluded from this analysis (see text for more details).
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Mto this risk. Finally, to establish baseline demographic char-
acteristics and comorbidities that might influence the deci-
sion to administer adjuvant vancomycin, we restricted our
analysis to patients admitted at least 1 day before surgery.
To isolate the effect of antibiotics administered on the day
of surgery, we further excluded patients given antibiotics
earlier in the admission.Although this excludes a substantial
fraction of CABG patients, it is important in identifying po-
tential confounders and thus ensuring the validity of our
findings. It is also likely that the findings from our analysis
would not be applicable to all CABG patients. We also do
not analyze patients who received alternate antibiotic regi-
mens, inasmuch as the small group sizes preclude meaning-
ful analysis.
In conclusion, our analysis suggests that administration
of adjuvant vancomycin for SSI prophylaxis does not in-
crease the risk of CDI. The decision about whether to ad-
minister vancomycin should be made on the basis of other
considerations. Given our finding that nearly half of all
CABG patients received vancomycin in the most recent
year of our study, and the substantial heterogeneity in prac-
tice with respect to its use, further research should focus on
defining the risks and benefits of its administration.References
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